#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Sex differences in semaglutide muscle loss
A July 2026 study finds female ob/ob mice are protected from semaglutide-induced muscle loss while males are not. What the finding means and what it does not.
ONWARDS 8: icodec plus semaglutide in T2D
ONWARDS 8 found that adding weekly semaglutide to weekly insulin icodec cut HbA1c by 1.23 points and body weight by 3.85 kg, with low hypoglycaemia rates.
Tirzepatide, CAVI, and arterial stiffness
A 2026 retrospective cohort found tirzepatide reduced CAVI from borderline to normal, alongside weight loss and glycaemic improvements, over 12.7 months.
Dapagliflozin plus semaglutide: BMI classes
A 328-patient Saudi cohort: proportional BMI response to dapagliflozin is uniform across obesity classes; semaglutide add-on helps most in class I.
GLP-1 drugs and micronutrient risk
How GLP-1 receptor agonists and dual incretin drugs create vitamin and mineral gaps, which nutrients are most at risk, and what monitoring looks like.
GLP-1 neuro research: what 20 years shows
A 2026 bibliometric analysis mapped 1,202 publications on GLP-1 receptor agonists in neurodegenerative disease from 2006 to 2025.
Incretins after bariatric surgery
A US cohort of 208,155 post-bariatric patients: tirzepatide beat semaglutide on weight loss (17.2% vs 12.0%). No significant cardiovascular signal either way.
Orforglipron for sleep apnea: ATTAIN-OSA
ATTAIN-OSA is testing an oral GLP-1 pill against sleep apnea. Here is what the 712-participant protocol measures and how it compares to SURMOUNT-OSA.
Semaglutide and OA: beyond weight loss
A 2026 preclinical study shows semaglutide reduces cartilage damage and joint pain without weight change, via GLP-1R activation of autophagy in chondrocytes.
Semaglutide in schizophrenia: HISTORI trial
Three randomised trials show semaglutide cuts weight and blood sugar in antipsychotic-treated patients without worsening psychiatric symptoms.
Tirzepatide vs semaglutide: real-world data
A 511-patient real-world study in Mayo Clinic Proceedings found tirzepatide produced 16.6% vs 13.4% mean weight loss for semaglutide over 12 months.
Bofanglutide vs semaglutide in Chinese T2D
Ann Intern Med Phase 2b: bofanglutide 18 mg biweekly cut HbA1c by 2.28 points versus 1.60 for semaglutide 1 mg weekly in Chinese patients with type 2 diabetes.